The short version of immunomodulation fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-05 and is reviewed periodically as new material appears.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | 28 residues; not a small-molecule compound |
| Molecular mass | About 3,106 Da | Monoisotopic mass of the unmodified chain |
| N-terminal group | Acetylated serine | Present in both native and synthetic forms |
| Secondary structure | Disulfide-constrained loop | One bridge between two cysteine residues |
| Typical source | Solid-phase synthesis | Early isolates came from bovine thymus extracts |
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
In pharmacology and toxicology, a route of administration (ROA) is the way by which a drug, fluid, poison, or other substance is introduced into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration. Routes can also be classified based on where the target of action is. Action may be topical (local), enteral (system-wide effect, but delivered through the gastrointestinal tract), or parenteral (systemic action, but is delivered by routes other than the GI tract). Route of administration and dosage form are aspects of drug delivery.
Philip E. Dawson is a scientist and academic leader, known for his contributions to the field of chemistry, particularly in synthetic protein chemistry and peptide science. He currently serves as the Dean of Graduate and Postdoctoral Studies at Scripps Research, where he is also a professor in the Department of Chemistry.
== Cause == There is a disc between each of the vertebrae in the spine. A healthy, well-hydrated disc will contain a great deal of water in its center, known as the nucleus pulposus, which provides cushioning and flexibility for the spine. Much of the mechanical stress that is caused by everyday movements is transferred to the discs within the spine and the water content within them allows them to effectively absorb the shock. At birth, a typical human nucleus pulposus will contain about 80% water. However natural daily stresses and minor injuries can cause these discs to gradually lose water as the annulus fibrosus, or the tough outer fibrous material of a disc, weakens. Because degenerative disc disease is largely due to natural daily stresses, the American Academy of Orthopaedic Manual Physical Therapists have suggested it is not truly a "disease" process. This water loss makes the discs more flexible and results in the gradual collapse and narrowing of the gap in the spinal column. As the space between vertebrae gets smaller, extra pressure can be placed on the discs causing tiny cracks or tears to appear in the annulus. If enough pressure is exerted, it is possible for the nucleus pulposus material to seep out through the tears in the annulus and can cause what is known as a herniated disc. As the two vertebrae above and below the affected disc begin to collapse upon each other, the facet joints at the back of the spine are forced to shift which can affect their function.
The study of diagenesis in rocks is used to understand the geologic history they have undergone and the nature and type of fluids that have circulated through them. From a commercial standpoint, such studies aid in assessing the likelihood of finding various economically viable mineral and hydrocarbon deposits. The process of diagenesis is also important in the decomposition of bone tissue.
Sources: en.wikipedia.org
==== Limitation on overall itemized deductions ==== Itemized deductions are reduced by 2/37 of the lesser of the amount of the itemized tax deductions or the taxable income that is within the 37%-rate marginal tax bracket. As an exception, the qualified business income deduction under 26 U.S.C. § 199A is not subject to the limitation.
Singapore's urbanisation means that it has lost 95% of its historical forests, and now over half of the naturally occurring fauna and flora in Singapore is present in nature reserves, such as the Bukit Timah Nature Reserve and the Sungei Buloh Wetland Reserve, which comprise only 0.25% of Singapore's land area. In 1967, to combat this decline in natural space, the government introduced the vision of making Singapore a "garden city", aiming to improve quality of life. Since then, nearly 10% of Singapore's land has been set aside for parks and nature reserves. The government has created plans to preserve the country's remaining wildlife. Singapore's well known gardens include the Singapore Botanic Gardens, a tropical garden and Singapore's first UNESCO World Heritage Site.
== Pathophysiology == Solar purpura is believed to be caused by skin damage due to chronic sun exposure, which leads to dermal atrophy. As a result of the dermal atrophy, the dermal connective tissue cannot support the microvasculature, and the result is extravasation of blood into the dermis. This results in visible purple spots on the skin.
Furthermore, the marked brocho-constriction produced by injections of histamine was not reversed by either l-synephrine or d,l-synephrine. In experiments with isolated sheep carotid artery, d-, l- and d,l-synephrine all showed some vasoconstrictor activity: l-synephrine was the most potent, producing strong contractions at a concentration of 1:10000. d-Synephrine was about 1/2 as potent as the l-isomer, but d,l-synephrine (which would have been expected to have a potency of 1/2 that of l-synephrine even if the d-isomer were completely inactive) did not produce significant and irregular contractions until a concentration of 1:2500had been reached, implying an inhibitory interaction between the two enantiomers. Qualitatively similar results were obtained in a rabbit ear preparation: 25 mg l-synephrine produced significant (50%) vasoconstriction, while the same concentration of d-synephrine elicited essentially no response. In contrast, d,l-synephrine did not produce any constriction up to 25 mg, but 25 – 50 mg caused a relaxation of the blood vessels, which again suggested that the d-isomer might be inhibiting the action of the l-isomer. Experiments on strips of rabbit duodenum showed that l-synephrine caused a modest reduction in contractions at a concentration of 1:17000, but that the effects of the d- and d,l- forms were much weaker. Racemic synephrine, given intramuscularly, or by instillation, was found to significantly reduce the inflammation caused by instillation of mustard oil into the eyes of rabbits.
=== Grand Lodge of Havana === In 1868, under the authority of GOCA, a number of Lodges in Havana chartered the Gran Logia de la Habana (English: Grand Lodge of Havana), but this Lodge was formally dissolved with the outbreak of the Ten Years' War. This Grand Lodge had only existed for less than a year.
Sources: en.wikipedia.org
=== Operation Theater Complex === The Operation Theater Complex was completed with PKR 260 million and was finally inaugurated on the Saturday 27 April 2019 having four State-of-the-art Operation theaters with a total capacity of 60 beds of which 10 are in the surgical ICU.
Whereas increasing the dose of opioid can be an effective way to overcome tolerance, doing so to compensate for opioid-induced hyperalgesia may worsen the patient's condition by increasing sensitivity to pain while escalating physical dependence. This "uncommon but important phenomenon [can be] seen with high-dose opioid therapy." However, the conclusion of a report published in the Journal of Pain and Palliative Care Pharmacotherapy suggests that "[h]yperalgesia shares a common mechanism with tolerance and it may be that hyperalgesia is a manifestation of tolerance itself."
==== Renal and biliary excretion ==== Drugs tightly bound to proteins (i.e. not in the free fraction) are not available for renal excretion. Filtration depends on a number of factors including the pH of the urine. Drug interactions may affect those points.
==== 2009–2015 ==== The JWP published its report on elements 113–116 and 118 in 2011. It recognised the JINR–LLNL collaboration as having discovered elements 114 and 116, but did not accept either team's claim to element 113 and did not accept the JINR–LLNL claims to elements 115 and 118. The JINR–LLNL claim to elements 115 and 113 had been founded on chemical identification of their daughter dubnium, but the JWP objected that current theory could not distinguish between superheavy group 4 and group 5 elements by their chemical properties with enough confidence to allow this assignment. The decay properties of all the nuclei in the decay chain of element 115 had not been previously characterised before the JINR experiments, a situation which the JWP generally considers "troublesome, but not necessarily exclusive", and with the small number of atoms produced with neither known daughters nor cross-reactions the JWP considered that their criteria had not been fulfilled. The JWP did not accept the Riken team's claim either due to inconsistencies in the decay data, the small number of atoms of element 113 produced, and the lack of unambiguous anchors to known isotopes. In early 2009, the Riken team synthesised the decay product 266Bh directly in the 248Cm + 23Na reaction to establish its link with 278113 as a cross-bombardment. They also established the branched decay of 262Db, which sometimes underwent spontaneous fission and sometimes underwent the previously known alpha decay to 258Lr.
== Skin == Basal cell carcinoma Squamous cell carcinoma Squamous cell skin cancer Skin adnexal tumors (e.g. sebaceous carcinoma) Melanoma Merkel cell carcinoma Keratoacanthoma Sarcomas of primary cutaneous origin (e.g. dermatofibrosarcoma protuberans) Lymphomas of primary cutaneous origin (e.g. mycosis fungoides)
Sources: en.wikipedia.org
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.